Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Highnoon LaboratoriesKAR:HINOON -0.45%96 Interest Coverage is 94.90 as of Mar. 2026, which is 51% above its 10-year median of 62.81. GuruFocus rates KAR:HINOON with a GF Score™ of 96/100 and a GF Value™ of ₨1,019.72 (Fairly Valued). The stock has 3 warning signs investors should review. Among 686 Drug Manufacturers companies, Highnoon Laboratories ranks better than 73.91% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Highnoon Laboratories's
Operating Income
for the
three
months ended in Mar. 2026 was ₨1,881 Mil. Highnoon Laboratories's Interest Expense for the
three
months ended in Mar. 2026 was ₨-20 Mil.
Highnoon Laboratories's interest coverage for the quarter that ended in Mar. 2026 was 94.90.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Highnoon Laboratories Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Highnoon Laboratories's Interest Coverage or its related term are showing as below:
KAR:HINOON'
s Interest Coverage Range Over the Past 10 Years
Min: 12.65 Med: 62.81 Max: 213.47
Current: 62.21
KAR:HINOON's Interest Coverage is ranked better than 73.91% of 686
companies
in the Drug Manufacturers industry
Industry Median: 12.645
vs KAR:HINOON: 62.21
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Highnoon Laboratories Interest Coverage Related Terms
Highnoon Laboratories Interest Coverage Historical Data
* Premium members only.
The historical data trend for Highnoon Laboratories's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
KAR:HINOON vs LLY, JNJ, ABBV: Interest Coverage Comparison
For the Drug Manufacturers - General subindustry, Highnoon Laboratories's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Highnoon Laboratories Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Highnoon Laboratories's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Highnoon Laboratories's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Highnoon Laboratories (KAR:HINOON) has a Interest Coverage of 94.90 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Highnoon Laboratories and its competitors. This is 51% above median its historical median of 62.81. Over the past decade, Highnoon Laboratories' Interest Coverage has ranged from 12.65 to 213.47. According to the industry distribution chart, Highnoon Laboratories ranks #179 out of 686 companies in the Drug Manufacturers industry, placing it in the top 26.1%.
Is Highnoon Laboratories' Interest Coverage too high?
Highnoon Laboratories' current Interest Coverage of 94.90 is 51% above median its 10-year median of 62.81. Over the past 10 years, this metric has ranged from a low of 12.65 to a high of 213.47. The Drug Manufacturers industry median Interest Coverage is 12.65. Highnoon Laboratories' value of 94.90 is 650.5% above this industry median. Based on the distribution chart, Highnoon Laboratories ranks #179 out of 686 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Highnoon Laboratories has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Highnoon Laboratories' Interest Coverage compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Highnoon Laboratories ranks #179 out of 686 companies for Interest Coverage. This puts Highnoon Laboratories in the upper half of its industry. The industry median Interest Coverage is 12.65. Highnoon Laboratories' value of 94.90 is 650.5% above this benchmark. Historically, Highnoon Laboratories' own Interest Coverage has ranged from 12.65 to 213.47 over the past decade. While the company's 10-year median is 62.81 vs. the industry median of 12.65, Highnoon Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.65, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Highnoon Laboratories's current Interest Coverage of 94.90 is 650.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Highnoon Laboratories and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Highnoon Laboratories's current Interest Coverage is 94.90, which is 51% above median its own 10-year median of 62.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Highnoon Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Highnoon Laboratories (KAR:HINOON) is currently considered Fairly Valued. The stock's GF Value™ is ₨1,019.72, compared to a current price of ₨961.21 — trading 5.7% below its estimated fair value. The current Interest Coverage is 94.90, which is 51% above median its 10-year median of 62.81 and 650.5% above the Drug Manufacturers industry median of 12.65. Highnoon Laboratories' overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Highnoon Laboratories (KAR:HINOON), the current Interest Coverage is 94.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Highnoon Laboratories (KAR:HINOON) Overvalued in 2026?
Based on GuruFocus' analysis, Highnoon Laboratories stock appears to be undervalued.
The current stock price of ₨961.21 is trading 5.7% below its estimated GF Value™ of ₨1,019.72.
GuruFocus considers Highnoon Laboratories to be Fairly Valued.
Key valuation signals for KAR:HINOON:
Interest Coverage: 94.90 (51% above median its 10-year median of 62.81)
GF Value™: ₨1,019.72 vs. price of ₨961.21 (5.7% below fair value)
Industry Position: 650.5% above the Drug Manufacturers median (#179 of 686)
No single metric tells the full story. See the KAR:HINOON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Highnoon Laboratories Ltd is a company engaged in the manufacture, import, sale, and marketing of pharmaceutical and allied consumer products. It focuses on the alimentary tract and metabolism, antihistamines, anti-infectives, cardiovascular, endocrine, hematology, musculoskeletal, nervous system, parasitology, respiratory, and urinary. Its products include AIRTAL (Aceclofenac); ARIA (ketotifen); ARTECXCIN, and artrodar (diacerein). Its other products include Asthavent, AXESOME, Bezisox, Betatec, and many more.
96GF Score
Get the complete analysis for KAR:HINOON
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:HINOON has been successfully added to your 
